Webinar Recording: New Patenting Strategies for Life Science Inventors
Webinar hosted by the Penn Center for Innovation with Dr. Kathryn Doyle, Partner, Saul Ewing Arnstein & Lehr.
Webinar Recording: Penn Health-Tech
Katherine Reuther, Ph.D., MBA, Executive Director of the Penn Center for Health-Devices and Technology discusses resources to support your medical device idea.
Success stories in gene therapy
Scientific American recently featured four stories on advancements in gene therapy.
Penn Medicine researchers receive prestigious NIH 2021 Director’s Awards
The grants, totaling more than $8 million, will support seven high-risk, high-reward research projects
Pennovation Lab welcomes new tenant Interius BioTherapeutics to its innovation ecosystem
Interius BioTherapeutics has signed a 17,743 SF lease advancing cell and gene therapy research at the Pennovation Works innovation ecosystem.
Washington Post special features on mRNA foundational technology inventors
The Washington Post ran two feature articles profiling Drew Weissman, MD, PhD, the Roberts Family Professor of Vaccine Research, and Katalin Karikó, PhD, an adjunct professor of Neurosurgery.
Two pioneering RNA scientists win the 2021 Dr. Paul Janssen Award for Biomedical Research
The foundational work that enabled the use of messenger RNA (mRNA) in vaccine development that they're receiving the 2021 Dr. Paul Janssen Award for Biomedical Research,
Penn mRNA Scientists Drew Weissman and Katalin Karikó Receive 2021 Lasker Award, America’s Top Biomedical Research Prize
Drs. Weissman and Karikó’s mRNA technology is recognized for enabling rapid development of highly effective COVID-19 vaccines.
Penn inventors make the mRNA-based COVID vaccines possible
Drew Weissman, MD, PhD, the Roberts Family Professor of Vaccine Research, and Katalin Karikó, PhD, an adjunct professor of Neurosurgery at Penn, have been awarded multiple prestigious prizes.
Luxturna inventor Jean Bennett starts a new gene therapy company to tackle rare diseases left behind by pharma, VCs
Jean Bennett, who designed and co-developed Luxturna, approved in 2018 for a rare form of blindness, had kept building new gene therapies for eye diseases at her University of Pennsylvania lab.